HomeAbout

TL;DR CNBC


Roche enters obesity market with Carmot takeover but drugs may not be available until 2030 - TL;DR CNBC

Roche enters obesity market with Carmot takeover but drugs may not be available until 2030

Publishing timestamp: 2023-12-04 12:04:47


Summary

Roche Pharmaceuticals is set to acquire anti-obesity drug developer Carmot Therapeutics. The deal will provide Roche access to Carmot's research and development portfolio, including promising drug candidates for oral obesity treatments. The acquisition is seen as an opportunity for Roche to compete with Novo Nordisk and Eli Lilly in the global weight loss drugs market. However, it may take several years before these drugs are widely available.


Sentiment: POSITIVE

Tickers: ROG-CHNOVO.B-DKLLY

Keywords: roche holding ageli lilly and conovo nordisk a/sbusinessbiotechnologybusiness newsbiotech and pharmaceuticalshealth care industry

Source: https://www.cnbc.com/2023/12/04/roche-enters-obesity-market-with-carmot-takeover.html


Developed by Leo Phan